ANGELALIGN (06699) rose more than 8% during trading, and as of press time, the stock price was up 7.24%, trading at HK$74.10 with a turnover of HK$142 million.

ANGELALIGN announced its interim results, with first-half revenue reaching $161.4 million USD, representing a year-on-year increase of 33.1%. Adjusted net profit was $19.5 million USD, up 84.8% year-on-year. Profit attributable to owners reached $14.643 million USD, surging 362.65% compared to the same period last year.

During the reporting period, the company's total number of clear aligner cases grew significantly by 47.7% year-on-year to approximately 225,800 cases. Among these, international market cases increased 103.5% year-on-year to about 117,200 cases, surpassing the 108,600 cases in the China market, demonstrating remarkable results from its global expansion strategy.

Goldman Sachs issued a research report stating that ANGELALIGN's first-half revenue of $161 million USD, up 33% year-on-year, exceeded expectations, primarily driven by rapid overseas business expansion. The gross margin remained stable at 62.4%, consistent with the same period last year. While the domestic business underwent strategic price adjustments, it maintained good profitability levels, and the overseas gross margin expanded from 58.3% in the same period last year to 61.2%.

Management raised its full-year case volume guidance to 490,000-500,000 cases, representing a year-on-year growth of 36% to 39%.